Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...
(Alliance News) - Stock prices in London closed higher on Monday, as investors appear to remain unphased by US President Donald Trump's earlier threats of 25% tariffs on steel and aluminium imports.